PDF(Pubmed)
Abstract：
BACKGROUND: 68Ga-PSMA PET/CT is superior to standard-of-care imaging for detecting regional and distant metastatic recurrent prostate cancer. The objective of our study was to evaluate the performance of 68Ga-PSMAPET/CT in our patient population, using the new PSMA-RADS version 2.0.
METHODS: A total of 128 patients scanned with 68Ga-PSMA PET/CT for detection of recurrence after RP were analyzed with PSMA-RADS version 2.0. For the analysis of the detection rate, categories PSMA-RADS 3 to 5 were considered as \"positive for malignancy\" and 1-2 as \"negative\".
RESULTS: According to PSMA-RADS v2.0, we classified patients as follows: 23 patients without PSMA-RADS because they were negative; PSMA-RADS 1: 10 patients; PSMA-RADS 2: 4 patients; PSMA-RADS 3A: 11 patients; PSMA-RADS 3B: 2 patients; PSMA-RADS 3C: 2 patients; PSMA-RADS 3D: 2 patients; PSMA-RADS 4: 13 patients; PSMA-RADS 5: 61 patients.
CONCLUSIONS: The overall detection rate of 68Ga-PSMA PET/CT was 71%. By dividing the patients into fourgroups according to PSA level before examination, we obtained the following detection rates: PSA < 0.2 ng/mL 38%; 0.2 ≤ PSA < 0.5 ng/mL 57%; 0.5 ≤ PSA ≤ 1 ng/mL 77%; and PSA > 1 ng/mL 95%.
CONCLUSIONS: Using PSMA-RADS version 2.0, we obtained detection rate values comparable with recent literature both in absolute terms and in relation to different PSA levels.
METHODS: A total of 128 patients scanned with 68Ga-PSMA PET/CT for detection of recurrence after RP were analyzed with PSMA-RADS version 2.0. For the analysis of the detection rate, categories PSMA-RADS 3 to 5 were considered as \"positive for malignancy\" and 1-2 as \"negative\".
RESULTS: According to PSMA-RADS v2.0, we classified patients as follows: 23 patients without PSMA-RADS because they were negative; PSMA-RADS 1: 10 patients; PSMA-RADS 2: 4 patients; PSMA-RADS 3A: 11 patients; PSMA-RADS 3B: 2 patients; PSMA-RADS 3C: 2 patients; PSMA-RADS 3D: 2 patients; PSMA-RADS 4: 13 patients; PSMA-RADS 5: 61 patients.
CONCLUSIONS: The overall detection rate of 68Ga-PSMA PET/CT was 71%. By dividing the patients into fourgroups according to PSA level before examination, we obtained the following detection rates: PSA < 0.2 ng/mL 38%; 0.2 ≤ PSA < 0.5 ng/mL 57%; 0.5 ≤ PSA ≤ 1 ng/mL 77%; and PSA > 1 ng/mL 95%.
CONCLUSIONS: Using PSMA-RADS version 2.0, we obtained detection rate values comparable with recent literature both in absolute terms and in relation to different PSA levels.
摘要：
背景：68Ga-PSMAPET/CT在检测区域性和远处转移性复发性前列腺癌方面优于标准护理成像。我们研究的目的是评估68Ga-PSMAPET/CT在我们患者人群中的表现，使用新的PSMA-RADS2.0版。
方法：用PSMA-RADS2.0版对128例患者进行68Ga-PSMAPET/CT扫描以检测RP后复发。为了分析检测率，PSMA-RADS3至5类被认为是“恶性肿瘤阳性”，1-2类被认为是“阴性”。
结果：根据PSMA-RADSv2.0，我们将患者分类如下：23例无PSMA-RADS患者，因为它们是阴性的；PSMA-RADS1:10例；PSMA-RADS2:4例；PSMA-RADS3A：11例；PSMA-RADS3B：2例；
结论：68Ga-PSMAPET/CT的总检出率为71%。根据检查前的PSA水平将患者分为四组，我们获得了以下检出率:PSA<0.2ng/mL38%;0.2≤PSA<0.5ng/mL57%;0.5≤PSA≤1ng/mL77%;PSA>1ng/mL95%.
结论：使用PSMA-RADS2.0版，我们获得了与最近文献相当的绝对和与不同PSA水平相关的检出率值。
方法：用PSMA-RADS2.0版对128例患者进行68Ga-PSMAPET/CT扫描以检测RP后复发。为了分析检测率，PSMA-RADS3至5类被认为是“恶性肿瘤阳性”，1-2类被认为是“阴性”。
结果：根据PSMA-RADSv2.0，我们将患者分类如下：23例无PSMA-RADS患者，因为它们是阴性的；PSMA-RADS1:10例；PSMA-RADS2:4例；PSMA-RADS3A：11例；PSMA-RADS3B：2例；
结论：68Ga-PSMAPET/CT的总检出率为71%。根据检查前的PSA水平将患者分为四组，我们获得了以下检出率:PSA<0.2ng/mL38%;0.2≤PSA<0.5ng/mL57%;0.5≤PSA≤1ng/mL77%;PSA>1ng/mL95%.
结论：使用PSMA-RADS2.0版，我们获得了与最近文献相当的绝对和与不同PSA水平相关的检出率值。
